Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.

Although a higher proportion of patients treated with monthly pegloticase also achieved an overall tophus CR compared to placebo-treated patients at each time point, these differences did not reach statistical significance (Table 3 ).

also in 111,027 other papers